- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Quarterly Report on Form 10-Q for the period ending March 31, 2023 of Ikena Oncology, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:
Date: May 15, 2025 | By: | /s/ Mark Manfredi | |
Mark Manfredi, Ph.D. | |||
President and Chief Executive Officer (Principal Executive Officer) | |||
|
By: | /s/ Jotin Marango | |
Jotin Marango | |||
Chief Financial Officer and Head of Corporate Development (Principal Financial Officer and Principal Accounting Officer) | |||
|
|
|
|